Search results for "vegf"

showing 10 items of 148 documents

The Expression and Prognostic Significance of VEGF and CXCR4 in Gastric Cancer: Correlation with Angiogenesis, Lymphangiogenesis and Progression

2022

The cellular response to hypoxia includes the expression of hypoxia-inducible factor-1 (HIF-1) and its target genes: vascular endothelial growth factor (VEGF) and CXC chemokine receptor 4 (CXCR4). The aim of this study was to investigate the expression and prognostic significance of VEGF and CXCR4, which are responsible for angiogenesis and progression in gastric cancer. Twenty-eight gastric cancer patients were analyzed. The mRNA expression was examined in primary tumors and corresponding normal gastric mucosa by RT-PCR. The protein level was examined by immunohistochemistry staining. The high expression of VEGF and CXCR4 was found in 71.0 and 64.0% of tumors, respectively. The mean levels…

Microbiology (medical)gastric cancer; VEGF; CXCR4; angiogenesis; lymphangiogenesis; lymph node metastasesGeneral MedicineMolecular BiologyMicrobiologyCurrent Issues in Molecular Biology
researchProduct

Serum VEGF and b-FGF profiles after tension-free or conventional hernioplasty.

2005

Angiogenesis is strongly influenced by vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (b-FGF), whose production is also regulated by interferon (IFN)-gamma and interleukin (IL)-10. The aim of this study was to evaluate the modifications of serum VEGF, b-FGF, IFN-gamma and IL-10 levels in patients with inguinal hernia undergoing hernioplasty with the Lichtenstein technique (LH) using polypropylene mesh or with Bassini open conventional inguinal hernia repair (BH). MATERIALS AND METHODS: Randomly, 16 patients underwent BH, and 16 were treated with the LH technique using polypropylene mesh. Blood samples were collected 24 h prior to surgery and then 6, 24, 48 and …

AdultMaleVascular Endothelial Growth Factor Amedicine.medical_specialtyAngiogenesisBasic fibroblast growth factorUrologyEnzyme-Linked Immunosorbent AssayHernia InguinalStatistics Nonparametricchemistry.chemical_compoundInterferon-gammaMedicineHumansIFN-γMeshAnalysis of Variancebusiness.industryInterleukinMiddle AgedSurgical Meshmedicine.diseaseVEGFSurgeryInterleukin-10Vascular endothelial growth factorInterleukin 10Inguinal herniachemistryHernioplastyIL-10SurgeryCytokine secretionFibroblast Growth Factor 2b-FGFbusinessAbdominal surgery
researchProduct

Análisis de mediadores moleculares implicados en angiogénesis en pacientes con cáncer de pulmón no microcítico: determinación de su valor como biomar…

2012

El cáncer de pulmón constituye un importante problema de salud pública, siendo el cáncer con los índices de mortalidad más elevados. Su diagnóstico se ve dificultado por la ausencia de síntomas en pacientes con tumores en estado precoz, diagnosticándose la mayoría de casos en fases ya avanzadas. Además la importancia del cáncer de pulmón radica en su mal pronóstico, ya que a pesar de los avances en el diagnóstico y en la terapéutica, el índice de supervivencia media tras 5 años es aproximadamente del 15%. La neovascularización tumoral, por medio de los procesos de angiogénesis, vasculogénesis y linfangiogénesis, resulta clave para el crecimiento y diseminación del tumor y se inicia ya en et…

biomarcadoresUNESCO::CIENCIAS MÉDICASUNESCO::CIENCIAS DE LA VIDA:CIENCIAS MÉDICAS [UNESCO]angiogénesisVEGFoncología:CIENCIAS DE LA VIDA [UNESCO]cáncer de pulmón
researchProduct

Engineered microenvironments for synergistic VEGF - Integrin signalling during vascularization

2017

We have engineered polymer-based microenvironments that promote vasculogenesis both in vitro and in vivo through synergistic integrin-growth factor receptor signalling. Poly(ethyl acrylate) (PEA) triggers spontaneous organization of fibronectin (FN) into nanonetworks which provide availability of critical binding domains. Importantly, the growth factor binding (FNIII12-14) and integrin binding (FNIII9-10) regions are simultaneously available on FN fibrils assembled on PEA. This material platform promotes synergistic integrin/VEGF signalling which is highly effective for vascularization events in vitro with low concentrations of VEGF. VEGF specifically binds to FN fibrils on PEA compared to …

MaleVascular Endothelial Growth Factor AIntegrinsBiophysicsNeovascularization PhysiologicBioengineeringpoly(ethyl acrylate)ArticleBiomaterialsHuman Umbilical Vein Endothelial CellsImage Processing Computer-AssistedAnimalsHumansPhosphorylationExtracellular Signal-Regulated MAP KinasesFibronectinTissue EngineeringPhospholipase C gammaProtein assemblyVascularizationVEGFFibronectinsMice Inbred C57BLCellular MicroenvironmentMechanics of MaterialsFocal Adhesion Protein-Tyrosine KinasesFISICA APLICADAMutationCeramics and CompositesINGENIERIA ELECTRICAGrowth factorsProtein BindingSignal Transduction
researchProduct

Papel de los receptores angiogénicos del VEGF en la apoptosis y migración celular de la leucemia linfática crónica-B. Correlación con los receptores …

2015

La leucemia linfática crónica B es un síndrome linfoproliferativo caracterizado por un balance entre la proliferación celular en los tejidos y la apoptosis espontánea que se traduce en un incremento progresivo de linfocitos neoplásicos en sangre periférica con invasión de ganglios y medula ósea. La migración celular depende de la expresión de factores pro-angiogénicos y de los receptores de quimiocinas de las células B-LLC, que favorecen la diseminación y prolongan la supervivencia de estas células. En este trabajo de investigación analizamos los niveles de expresión de los receptores angiogénicos VEGF-R1, VEGF-R2 y VEGF-R3 en células de LLC-B por citometría de flujo y PCR cuantitativa así …

UNESCO::CIENCIAS MÉDICASleucemia linfática crónica B:CIENCIAS MÉDICAS [UNESCO]vegfcxcr4
researchProduct

How to deal with second line dilemma in metastatic colorectal cancer? A systematic review and meta-analysis.

2019

e15006 Background: Monoclonal antibodies targeting epidermal growth factor receptor (EGFR) or vascular endothelial growth factor (VEGF) have demonstrated efficacy in combination with chemotherapy as second line for metastatic colorectal cancer (mCRC). However, there is still a paucity of evidence or guidelines suggesting the right sequential treatment in all RAS (KRAS/NRAS) wild type(wt)mCRC. Therefore, we aimed to evaluate the impact of these targeted therapies by reviewing literature data. Methods: We used Cochrane, EMBASE and Medline databases to select phase III clinical trials containing efficacy and safety data about chemotherapy (CT) or CT + targeted agents combination (Anti-VEGF an…

Cancer ResearchChemotherapybiologybusiness.industryColorectal cancermedicine.drug_classmedicine.medical_treatmentVEGF receptorsmedicine.diseaseMonoclonal antibodyVascular endothelial growth factorchemistry.chemical_compoundSecond lineOncologychemistryMeta-analysisCancer researchbiology.proteinMedicineEpidermal growth factor receptorbusinessJournal of Clinical Oncology
researchProduct

The McCAVE Trial: Vanucizumab plus mFOLFOX‐6 Versus Bevacizumab plus mFOLFOX‐6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma …

2019

Abstract Background Bevacizumab, a VEGF‐A inhibitor, in combination with chemotherapy, has proven to increase progression‐free survival (PFS) and overall survival in multiple lines of therapy of metastatic colorectal cancer (mCRC). The angiogenic factor angiopoetin‐2 (Ang‐2) is associated with poor prognosis in many cancers, including mCRC. Preclinical models demonstrate improved activity when inhibiting both VEGF‐A and Ang‐2, suggesting that the dual VEGF‐A and Ang‐2 blocker vanucizumab (RO5520985 or RG‐7221) may improve clinical outcomes. This phase II trial evaluated the efficacy of vanucizumab plus modified (m)FOLFOX‐6 (folinic acid (leucovorin), fluorouracil (5‐FU) and oxaliplatin) ver…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyVEGF‐AVanucizumab20BevacizumabAngiopoetin-26Organoplatinum CompoundsColorectal cancerLeucovorinPhases of clinical researchFirst‐line metastatic colorectal cancerAntibodies Monoclonal HumanizedVEGF-ADisease-Free SurvivalMetastasis03 medical and health sciencesFolinic acid0302 clinical medicineMetàstasiCàncer colorectalInternal medicineGastrointestinal CancerAntineoplastic Combined Chemotherapy ProtocolsmedicineClinical endpointHumansNeoplasm MetastasisAngiopoetin‐2business.industryHazard ratiomedicine.diseaseColorectal cancerOxaliplatinBevacizumab030104 developmental biologyOncologyFluorouracil030220 oncology & carcinogenesisCamptothecinFluorouracilbusinessColorectal NeoplasmsFirst-line metastatic colorectal cancermedicine.drug
researchProduct

Expression of endocan and vascular endothelial growth factor in recurrent minor aphthous ulcers

2019

Background Recurrent aphthous ulcers (RAU) are common painful inflammatory lesions of the mucous lining of the mouth. Endocan, previously identified as endothelial cell specific molecule-1, is implicated as a vital player in the regulation of several inflammatory processes. A number of inflammatory cytokines and pro-angiogenic growth factors including VEGF upregulate endothelial cells synthesis and expression of endocan. Material and methods Clinical scores of pain and ulcer size as well as level of endocan and VEGF were determined in swaps from aphthous ulcer and contra lateral normal mucosa in 30 patients (nine males and twenty one females) with age ranging from 18 to 45 years and mean ag…

0301 basic medicinemedicine.medical_specialtyVEGF receptorsGastroenterologyProinflammatory cytokine03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDownregulation and upregulationInternal medicineMedicineGeneral DentistryPain scoreOral Medicine and Pathologybiologybusiness.industryResearchMean agemedicine.disease:CIENCIAS MÉDICAS [UNESCO]Endothelial stem cellVascular endothelial growth factor030104 developmental biologychemistryUNESCO::CIENCIAS MÉDICASaphthous ulcerbiology.proteinbusiness030215 immunology
researchProduct

Significado pronóstico de la expresión del factor de crecimiento endotelial vascular (VEGF) y de genes implicados en las vías de señalización del VEG…

2022

El estudio de las características de la leucemia aguda mieloblástica (LMA) al diagnóstico es fundamental porque clasifica a los pacientes en grupos pronósticos para adaptar el tratamiento al riesgo de recaída y reducir la toxicidad. Sin embargo, existe un grupo de pacientes en los que no se detectan alteraciones citogenéticas o moleculares y cuya evolución es muy heterogénea. Diversos estudios han demostrado un aumento de la angiogénesis en la médula ósea de los pacientes con LMA así como de citoquinas proangiogénicas como el factor de crecimiento endotelial vascular (VEGF). Las células leucémicas inducen la angiogénesis a través del VEGF, que regula la proliferación, supervivencia, angiogé…

leucemia aguda mieloblásticaleucemia mieloide agudaUNESCO::CIENCIAS MÉDICAS:CIENCIAS MÉDICAS [UNESCO]factor de crecimiento endotelial vascularangiogénesisVEGF
researchProduct

Boron Ions: Simultaneous Boron Ion‐Channel/Growth Factor Receptor Activation for Enhanced Vascularization (Adv. Biosys. 1/2019)

2019

biologyChemistryVEGF receptorsIntegrinBiomedical Engineeringchemistry.chemical_elementGeneral Biochemistry Genetics and Molecular BiologyIonBiomaterialsFibronectinGrowth factor receptorbiology.proteinBiophysicsBoronIon channelAdvanced Biosystems
researchProduct